Erythropoietin (EPO) in acute kidney injury

98Citations
Citations of this article
113Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Erythropoietin (EPO) is a 30.4 kDa glycoprotein produced by the kidney, and is mostly well-known for its physiological function in regulating red blood cell production in the bone marrow. Accumulating evidence, however, suggests that EPO has additional organ protective effects, which may be useful in the prevention or treatment of acute kidney injury. These protective mechanisms are multifactorial in nature and include inhibition of apoptotic cell death, stimulation of cellular regeneration, inhibition of deleterious pathways, and promotion of recovery. In this article, we review the physiology of EPO, assess previous work that supports the role of EPO as a genera tissue protective agent, and explain the mechanisms by which it may achieve this tissue protective effect. We then focus on experimental and clinical data that suggest that EPO has a kidney protective effect. © 2011 Moore.

Cite

CITATION STYLE

APA

Moore, E., & Bellomo, R. (2011). Erythropoietin (EPO) in acute kidney injury. Annals of Intensive Care. Springer Verlag. https://doi.org/10.1186/2110-5820-1-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free